Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.
A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States. Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.
DFP-14927 is an amide bond of DFP-10917 to a carboxylic acid at the end of polyethylene glycol (PEG) with a molecular weight of 40,000, and it is extremely stable in human blood after intravenous administration, allowing for weekly treatment regimen. DFP-14927 is a drug delivery system (DDS) with a mechanism that allows selective release of DFP-10917 into cancer tissues by amidolysis of proteases that are highly expressed in them.
Compared to high molecular weight antibody-drug conjugates (ADCs), medium-sized PEG covalent conjugates are known to have retention in blood vessels around cancer and cancer cell membranes and higher permeability into tumors, and therefore, the concentration of DFP-10917 in cancer tissue can be measured by conventional analysis without the use of radioisotope technology.
Soon after the expected effective concentration of DFP-10917 in cancer tissue is confirmed in the study, we plan to conduct an expanded Phase I study, equivalent to a Phase II clinical trial, in patients with colorectal cancer who have failed existing approved drugs.
The composition of matter patent for DFP-14927 has been granted in the United States, Europe, Asian countries and others, which will enable global marketing of DFP-14927.
In collaboration with leading oncology hospitals in the U.S., we are considering the development of DFP-14927 in haematological cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in addition to solid tumors.
For our future global development and marketing strategy, we are considering collaboration with a major global pharmaceutical company that has strength and expertise in the oncology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
THALES28.2.2024 09:01:27 CET | Press release
Eseye Selects Thales to Streamline IoT Deployments With Seamless Connectivity Management
1NCE28.2.2024 08:16:26 CET | Press release
1NCE is Now Live With Nationwide IoT in Brazil
CA-GALDERMA28.2.2024 07:01:25 CET | Press release
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
DE-INCYTE27.2.2024 22:09:29 CET | Press release
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
GA-STONEBRANCH27.2.2024 19:25:26 CET | Press release
Stonebranch Announces Record-Breaking Growth in 2023, Sets Sights on Future Innovations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom